<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=319805651697215&amp;ev=PageView&amp;noscript=1">

Cryoport to Report Financial Results for Fiscal Third Quarter of 2015 and Provide Business Update on Thursday, February 5th

January 29, 2015

Lake Forest, CA, January 29, 2015 - Cryoport, Inc. (OTCBB:CYRX) (“Company”), the leading provider of advanced cryogenic logistics solutions for life sciences serving markets including immunotherapies, stem cells, cell lines, clinical research organizations, vaccine manufacturers, and reproductive medicine, today announced it will release its financial results for the fiscal third quarter ended December 31, 2014 on Thursday, February 5th.  

The Company will host an investor conference call at 10:00 AM EST on Thursday, February 5th to review its financial results and business outlook.  Participants should call (888) 523-1225 (United States) or (719) 325-2215 (International) and request the Cryoport call or provide confirmation code: 6985389. A live audio webcast of the call will also be available on the Investor Relations section of the Company’s website at www.cryoport.com. Please allow 10 minutes prior to the call to visit this site to download and install any necessary audio software.

An archive of the webcast will be available approximately two hours after completion of the live event and will be accessible on the Investor Relations section of the Company's website at www.cryoport.com for a limited time.  A dial-in replay of the call will also be available to those interested until February 12, 2015.  To access the replay, dial (877) 870-5176 (United States) or (858) 384-5517 (International) and enter code: 6985389.

About Cryoport, Inc.

Cryoport is the premier provider of cryogenic logistics solutions to the life sciences industry through its purpose-built proprietary packaging, information technology and specialized cold chain logistics expertise. We provide leading edge logistics solutions for biologic materials such as immunotherapies, stem cells, CAR-T cells, and reproductive cells for clients worldwide including points-of-care, CRO’s, central laboratories, biopharmaceuticals, contract manufacturing, health centers and university research. Our packaging is built around our proprietary Cryoport Express® liquid nitrogen dry vapor shippers, which are validated to maintain a constant -150°C temperature for a10 day dynamic shipment duration. Our information technology centers around our Cryoportal™ Logistics Management Platform, which facilitates management of the entire shipment process. Cryoport is the preferred cryogenic logistics solutions partner to the world’s largest shipping companies controlling more than 85% of the world’s air shipments. For more information, visit www.cryoport.com.

Forward Looking Statements

Statements in this news release which are not purely historical, including statements regarding Cryoport, Inc.’s intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. It is important to note that the company's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, risks and uncertainties associated with the effect of changing economic conditions, trends in the products markets, variations in the company's cash flow, market acceptance risks, and technical development risks. The company’s business could be affected by a number of other factors, including the risk factors listed from time to time in the company's SEC reports including, but not limited to, the annual report on Form 10-K for the year ended March 31, 2013. The company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Cryoport, Inc. disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.

Investor Contacts:
Todd Fromer / Garth Russell
tfromer@kcsa.com / grussell@kcsa.com
P: 1 212-682-6300

Tags: Frozen Shipping, shipping solution, Frozen, sales force, Life Sciences, Cold Chain Logistics, Dry Shipper, cold shipping, Clinical Trials Logistics